Cashu | Summary | SPRO

HomeWatchlistNewsSignalsPicks

DJI

+0.20%

SPX

+0.14%

IXIC

+0.27%

FTSE

+0.64%

N225

-0.01%

AXJO

+0.54%

HomeWatchlistNewsSignalsPicks

Stocks

0.00 (0.00%)

0.000

USD

At close at --,----

Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

About Us
Careers
Blog
News

Help & Support

Help Center
Contact Us
Pro Support

Legal

Privacy Policy
Terms of Use

Instagram YouTube

© 2024 Cashu PTY LTD.

Join our newsletter to keep up to date with us!

Overview

Loading chart...

Key Stats

Market Cap

157.08M

Dividend Yield

0.00%

P/E Ratio

-2.25

EPS

-1.27

Revenue

47.98M

Avg. Volume

58.16K

About

What does SPRO do?

Spero Therapeutics, based in Cambridge, Massachusetts, develops treatments for multi-drug resistant infections and rare diseases, with key products including SPR720, tebipenem HBr, and SPR206. The company went public on November 2, 2017, and employs 46 people.

Sector

💻 Health Care

IPO

CEO

Employees

Headquarters

Massachusetts, USA

Website

http://sperotherapeutics.com

Recently from Cashu

Spero Therapeutics: Promising Tebipenem HBr Trial Results Signal Breakthrough for cUTI Treatment

about 1 month ago

Spero Therapeutics Advances Tebipenem HBr After Promising cUTI Trial Results

about 2 months ago

Stocks

Health Care

spro

Spero Therapeutics

SPRO

-0.17 (-5.87%)

2.645

USD

At close at Jul 14, 20:37 UTC